Clinical trials: COVID-19; Immunity
SARS-CoV-2 Infection, COVID-19
A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United Kingdom
This is a study to evaluate the efficacy, immune response, and safety of a coronavirus disease 2019 (COVID-19) vaccine called SARS-CoV-2 rS with Matrix-M1 adjuvant in adults aged 18-84 years in the United Kingdom.
- Trial name
- NCT04583995
- Testing
- SARS-CoV-2 rS/Matrix M1-Adjuvant, Licensed seasonal influenza vaccine
- Where
- 33 sites in United Kingdom
- Volunteers
- 15,185 people, healthy volunteers welcome
- Sponsor
- Novavax
Covid19
Safety, Tolerability, and Immunogenicity of the COVID-19 Vaccine Candidates VBI-2902a and VBI-2905a
VBI-2902a and VBI-2905a are investigational vaccine candidates that use enveloped virus-like particle (eVLP) expression of a modified version of the SARS-CoV-2 spike (S) glycoprotein and are designed to induce neutralizing…
- Trial name
- NCT04773665
- Testing
- VBI-2902a, VBI-2905a
- Where
- 4 sites in Canada
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- VBI Vaccines Inc.
Pregnancy Complications, Covid19
Vitamin D Supplementarion in Pregnant Women at Risk and COVID-19
Vitamin D defiency during pregnancy is a major public health problem worldwide; In Spain, the average intake of vitamin D is lower than recommendations in an elevated percentage of the population, ranging from 50 to 95%…
- Trial name
- D-WOMAN (NCT04825093)
- Testing
- Vitamin D supplementation in pregnant women
- Where
- Spain
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Universidad de Granada
SARS-CoV-2
Safety and Immune Response of Adjuvanted SARS-CoV-2 (COVID-19) Beta Variant RBD Recombinant Protein (DoCo-Pro-RBD-1 + MF59®) and mRNA (MIPSCo-mRNA-RBD-1) Vaccines in Healthy Adults
This is a study of two experimental SARS-CoV-2 vaccines against the virus called SARS-CoV-2 virus. The first of the experimental vaccines is called DoCo-Pro-RBD-1 + M59® and contains a laboratory made protein which looks the same…
- Trial name
- NCT05272605
- Testing
- Adjuvanted SARS-CoV-2 beta variant RBD recombinant protein vaccine (DoCo-Pro-RBD-1 + MF59), SARS-CoV-2 beta variant RBD mRNA vaccine, Normal Saline
- Where
- 2 sites in Australia
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- University of Melbourne
SARS-CoV 2, COVID
Precision Immunology to Determine the Immune Response in Patients With COVID-19
To better understand the immune response to SARS-CoV-2 infection, we devised a precision immunology approach to systematically study the immune function of different patient cohorts
- Trial name
- NCT04360733
- Testing
- Blood draw
- Where
- Germany
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University of Bonn
Covid19, Non-specific Effects of Vaccines
Using BCG to Protect Senior Citizens During the COVID-19 Pandemic
Background: The virus SARS-CoV-2 has spread rapidly throughout the world. Seniors are at high risk of severe COVID-19 when infected.
- Conditions
- Covid19, Non-specific Effects of Vaccines, Heterologous Immunity, Morbidity
- Trial name
- NCT04542330
- Testing
- BCG-Denmark, Saline
- Where
- Denmark
- Volunteers
- 1,700 people, healthy volunteers welcome
- Sponsor
- Bandim Health Project
COVID 19
MURDOCK Cabarrus County COVID-19 Prevalence and Immunity (C3PI) Study
The objectives of this research is to: Assess perceptions, concerns, and practices related to the COVID-19 pandemic and mitigation strategies using the MURDOCK Study Community Registry and Biorepository population as a measure of…
- Trial name
- C3PI (NCT04424004)
- Testing
- COVID-19 PCR and serology testing
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Duke University
COVID, Sars-CoV2
Whole Blood Collection From Individuals in the Convalescent Phase of SARS-CoV-2 Infection
The study was not opened.
- Trial name
- NCT04409184
- Volunteers
- healthy volunteers welcome
- Sponsor
- Medical College of Wisconsin
SARS-CoV Infection, Covid19
Study of HEarT DiseAse and ImmuNiTy After COVID-19 in Ireland
SETANTA study will investigate the incidence of cardiac abnormalities as assessed by cardiac magnetic resonance imaging in unselected patients after acute SARS-CoV-2 infection and correlation with immunological response and…
- Conditions
- SARS-CoV Infection, Covid19, Cardiomyopathies
- Trial name
- SETANTA (NCT04823182)
- Testing
- Cardiovascular Magnetic Resonance Imaging
- Where
- Ireland
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Cardiovascular Research Institute Dublin
Covid19
Factors Influencing the COVID-19 Vaccine Immune Response According to Age and Presence or Not of a Past History of COVID-19
Age is the main risk factor associated with the severity of COVID-19. From the beginning of the vaccination campaign, elderly subjects are part of the priority population.
- Trial name
- COVIMMUNAGE (NCT05047718)
- Testing
- COVID-19 vaccine Pfizer (3 doses), COVID-19 vaccine Pfizer (2 doses), COVID-19 mRNA Vaccine Moderna (3 doses)
- Where
- 2 sites in France
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
COVID-19
Lymph Node Aspiration to Decipher the Immune Response of Beta-variant Recombinant Protein Booster Vaccine (VidPrevtyn Beta, Sanofi) Compared to a Bivalent mRNA Vaccine (Comirnaty Original/Omicron BA.4-5, BioNTech-Pfizer) in Adults Previously Vaccinated With at Least 3 Doses of COVID-19 mRNA Vaccine.
In order to investigate whether a germinal center response occurs following vaccine boost and to characterize it based on the type of vaccine received, we aim to analyze Spike and/or RBD-specific germinal center B cells within…
- Trial name
- LymphoBOOST (NCT05951920)
- Testing
- Lymph node aspiration / Blood sampling
- Where
- France
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Cancer
Immune Responses in Oncology Patients to Novel Coronavirus Vaccines (IROC)
The goals of this study are to assess initial or booster vaccine performance (safety and efficacy) and to collect serum and peripheral blood mononuclear cells (PBMCs) pre and post-vaccination to assess immune and other response…
- Trial name
- NCT04930055
- Testing
- COVID-19 Vaccination
- Where
- 2 sites in United States
- Volunteers
- 2,206 people, healthy volunteers welcome
- Sponsor
- Indiana University
SARS-CoV2 Infection
Coronavirus Pediatric Serological Study
The Coronavirus Pediatric Serological Study's aim is to provide a better insight of children's immune response after SARS-CoV-2 infection.
- Trial name
- CoPSS (NCT05128435)
- Testing
- Blood sample
- Where
- Belgium
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire Saint Pierre
Covid19
Characterisation of the Immune Response to SARS-CoV-2 / COVID-19
Emerging clinical details of the current SARS-CoV-2 pandemic have illustrated that there are multiple clinical presentations and outcomes of this viral infection.
- Trial name
- NCT04729452
- Testing
- blood test
- Where
- United Kingdom
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Cwm Taf University Health Board (NHS)
Multiple Sclerosis
Covid-19 Vaccine Immune Response in Multiple Sclerosis
Coronavirus (Covid-19) has affected millions of people worldwide. Vaccines to prevent Covid-19 infection have been offered to reduce the risk of infection.
- Trial name
- CoVaR-MS (NCT05269888)
- Testing
- Blood Test 1, Blood Test 2
- Where
- United Kingdom
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- University Hospitals of North Midlands NHS Trust
New Coronavirus Disease (COVID-19), Infection With SARS-CoV-2
Study of Immune Response During SARS-CoV-2 Infection - (COVID-19)
Study of the cellular immune response during the SARS-CoV-2 infection and identify cytokinic profiles in caregivers exposed to the virus with asymptomatic forms of COVID19, patients with an asymptomatic form followed in…
- Trial name
- CovImmune (NCT04355351)
- Testing
- blood sampling, additional blood tubes
- Where
- 3 sites in France
- Volunteers
- 303 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Nice
COVID-19
Immune Profiling of COVID19-patients Admitted to ICU
SARS-CoV-2 is the novel coronavirus responsible for COVID-19, coronavirus disease 2019. This new coronavirus was first detected in Wuhan, China in late December 2019.
- Trial name
- IMPROVISE (NCT04473131)
- Testing
- No intervention
- Where
- Qatar
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Hamad Medical Corporation
COVID-19, Virus Diseases
Bacillus Calmette-guérin Vaccination to Prevent COVID-19
Based on findings of the interim analysis of the ACTIVATE study showing 53% decrease of the incidence of all new infections with BCG vaccination, a new trial is designed aiming to validate if BCG can protect against COVID-19…
- Conditions
- COVID-19, Virus Diseases, Corona Virus Infection, Coronary Heart Disease
- Trial name
- ACTIVATEII (NCT04414267)
- Testing
- BCG vaccine
- Where
- 15 sites in Greece
- Volunteers
- 301 people, healthy volunteers welcome
- Sponsor
- Hellenic Institute for the Study of Sepsis
Influenza, Human, SARS-CoV-2 Infection
Does Repeat Influenza Vaccination Constrain Influenza Immune Responses and Protection
The objectives of this study are to understand the long-term consequences of repeated annual influenza vaccination among healthcare workers (HCWs) and to use statistical and mathematical modelling to elucidate the immunological…
- Trial name
- NCT05110911
- Testing
- Influenza vaccination: Fluarix Tetra, Vaxigrip Tetra, Fluquadri, Fluad Quad, Afluia Quad, Flucelvax Quad, SARS-CoV-2 vaccination: Comirnaty or Vaxzevria
- Where
- 6 sites in Australia
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- University of Melbourne
Diabetes Mellitus, Type 1
Anti-viral Action Against Type 1 Diabetes Autoimmunity
The study GPPAD-05 AVAnT1A is a phase 4 clinical trial intending to enroll 2252 children, who will be randomly assigned to receive COVID-19 vaccination (Comirnaty® 3 μg Omicron XBB.1.5 or new variant Comirnaty vaccines ) or…
- Trial name
- NCT06452654
- Testing
- Comirnaty Injectable Product, Sodium Chloride 0.9% Inj
- Where
- 9 sites in Austria, Belgium and 3 more
- Volunteers
- 2,252 people, healthy volunteers welcome
- Sponsor
- Technical University of Munich